ALX Oncology (Nasdaq: ALXO) reported a Q2 2026 GAAP net loss of $18.0 million, or $0.13 per basic and diluted share, compared with $25.9 million, or $0.49 per share, a year earlier. Lower R&D spending and the absence of a prior-year lease impairment narrowed the loss, while cash, cash equivalents and investments reached $153.4 million. Clinical milestones remain the main operating focus, with ALX2004 safety data expected in the second half of 2026 and an ASPEN-09-Breast readout targeted for mid-2027.
Core financial results
The quarter’s financial improvement came primarily from lower operating expenses. R&D expense declined by $4.9 million as costs associated with legacy trials fell, partially offset by continued investment in the ASPEN-09-Breast Phase 2 trial and the ALX2004 Phase 1 study.
The prior-year quarter also included a $3.2 million lease impairment charge, while Q2 2026 recorded a $0.2 million lease termination gain. A $0.9 million loss on debt extinguishment partially offset those benefits below the operating line.
| Metric | Q2 2026 | Q2 2025 | YoY change |
|---|---|---|---|
| R&D expense | $13.1 million | $18.0 million | Down about 27% |
| G&A expense | $5.1 million | $5.5 million | Down about 6% |
| Total operating expenses | $18.0 million | $26.6 million | Down about 32% |
| Operating loss | $(18.0) million | $(26.6) million | Loss narrowed about 32% |
| GAAP net loss | $(18.0) million | $(25.9) million | Loss narrowed about 31% |
| GAAP loss per share | $(0.13) | $(0.49) | Loss per share narrowed $0.36 |
| Non-GAAP net loss | $(14.3) million | $(20.6) million | Loss narrowed about 30% |
| Weighted-average diluted shares | 135.6 million | 53.4 million | Up about 154% |
A larger share base amplified the change in loss per share
ALX Oncology’s GAAP net loss narrowed by about 31%, but its loss per share fell by roughly 73%. The difference reflects the increase in weighted-average shares to 135.6 million from 53.4 million.
Consequently, the per-share comparison shows a substantially larger change than the absolute net-loss figures. The expense reductions still lowered the company’s operating loss, but not by as much as the EPS movement alone might suggest.
Clinical pipeline and upcoming milestones
Evorpacept
ALX Oncology reported exploratory Phase 1b/2 data at ESMO Breast Cancer 2026 for evorpacept combined with zanidatamab in heavily pretreated metastatic breast cancer. The company described promising and durable responses, particularly in patients with centrally confirmed HER2-positive disease and high CD47 expression, but the release did not provide numerical response data.
Enrollment in the Phase 2 ASPEN-09-Breast trial remains on schedule. The study is evaluating evorpacept with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer, with topline data from 80 patients expected in mid-2027.
ALX2004
The Phase 1 dose-escalation trial of ALX2004 continues to enroll patients with EGFR-expressing solid tumors. ALX Oncology expects to report initial safety data in the second half of 2026. The program remains at an early stage, so this update concerns enrollment and safety timing rather than demonstrated efficacy.
Liquidity and debt refinancing
Cash, cash equivalents and investments totaled $153.4 million at June 30, 2026, up from $48.3 million at December 31, 2025. ALX Oncology believes these resources are sufficient to fund planned operations through the first half of 2028.
In June, the company refinanced $10 million of existing debt with HSBC Ventures USA and secured the option to draw up to an additional $20 million through the end of June 2028. The secured multi-tranche facility provides for aggregate principal of up to $50 million, including $10 million that is uncommitted. Management said the refinancing lowered its cost of capital and increased financial flexibility, although the release did not provide comparative interest rates.
Recent insider transactions
The supplied insider dataset is internally inconsistent: its six-month aggregate reports no transactions, while its detailed ledger lists multiple 2026 transactions. The ledger entries below are presented as reported, without using them to infer insiders’ views of the company.
| Date | Insider | Role | Direction | Reported price | Reported value |
|---|---|---|---|---|---|
| July 1, 2026 | Shelly Wong | Officer | Sale | $2.04 | $2,864 |
| March 19, 2026 | Jason Lettmann | CEO | Sale | $2.17 | $26,715 |
| March 19, 2026 | Shelly Pinto | Officer | Sale | $2.17 | $1,960 |
| February 18, 2026 | Shelly Pinto | Officer | Sale | $2.27 | $1,283 |
| February 2, 2026 | Corey S. Goodman | Director and beneficial owner above 10% | Purchase | $1.57 | $4,999,999 |
| January 6, 2026 | Shelly Pinto | Officer | Sale | $1.11 | $4,357 |
Risks investors need to watch
- Clinical readout risk: The investment case remains tied to trial outcomes. ALX2004’s initial safety update and the 80-patient ASPEN-09-Breast readout have not yet occurred, and the reported ESMO findings came from exploratory analyses.
- Early-stage pipeline risk: ALX2004 is still in Phase 1 dose escalation, while evorpacept’s biomarker-driven strategy requires further validation in the ongoing Phase 2 trial.
- Ongoing funding requirements: ALX Oncology recorded an $18.0 million quarterly net loss and had a $758.7 million accumulated deficit. Its stated runway covers planned operations only through the first half of 2028, and additional debt draws would increase financial obligations.
- Larger share base: Weighted-average shares increased substantially from the prior-year quarter. This makes EPS comparisons less representative of the underlying change in absolute losses and affects future per-share economics.
Summary
ALX Oncology’s Q2 2026 results reflected lower spending rather than a commercial inflection: reduced legacy-trial costs and the absence of a prior-year impairment narrowed both GAAP and non-GAAP losses. The company enters its next clinical milestones with $153.4 million in cash and investments and a stated runway through the first half of 2028. The next material updates are ALX2004 safety data in the second half of 2026 and the ASPEN-09-Breast topline readout expected in mid-2027.
Find out more
Comments